{"id":554781,"date":"2021-07-27T18:26:01","date_gmt":"2021-07-27T18:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=554781"},"modified":"2021-07-27T18:26:01","modified_gmt":"2021-07-27T18:26:01","slug":"paroxysmal-nocturnal-hemoglobinuria-market-industry-analysis-treatment-pipeline-drugs-key-companies-including-apellis-pharmaceuticals-roche-novartis-alexion-pharmaceutical-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/paroxysmal-nocturnal-hemoglobinuria-market-industry-analysis-treatment-pipeline-drugs-key-companies-including-apellis-pharmaceuticals-roche-novartis-alexion-pharmaceutical-delveinsight_554781.html","title":{"rendered":"Paroxysmal Nocturnal Hemoglobinuria Market: Industry Analysis, Treatment, Pipeline Drugs &#038; Key Companies including Apellis Pharmaceuticals, Roche, Novartis, Alexion Pharmaceutical | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1627370340.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Paroxysmal Nocturnal Hemoglobinuria Market: Industry Analysis, Treatment, Pipeline Drugs &amp; Key Companies including Apellis Pharmaceuticals, Roche, Novartis, Alexion Pharmaceutical | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1627370340.jpeg\" alt=\"Paroxysmal Nocturnal Hemoglobinuria Market: Industry Analysis, Treatment, Pipeline Drugs &amp; Key Companies including Apellis Pharmaceuticals, Roche, Novartis, Alexion Pharmaceutical | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Paroxysmal Nocturnal Hemoglobinuria Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/paroxysmal-nocturnal-hemoglobinuria-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Paroxysmal Nocturnal Hemoglobinuria<\/a><\/strong> treatment has majorly been symptomatic and non-specific. Practices like an iron replacement, folic acid replenishment, blood transfusion and infection care have been in trend. Corticosteroids (e.g.prednisone) or anticoagulants (e.g. warfarin) are recommended in many cases to suppress the symptoms and to enhance the overall health of patients, but the needed steroid dose is too high to permit its daily use.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <strong>&#8220;<\/strong><strong>Paroxysmal Nocturnal Hemoglobinuria Market<\/strong><strong> Insights, Epidemiology, and Market Forecast-2030<\/strong><strong>&#8220;<\/strong><strong>&nbsp;<\/strong>report delivers an in-depth understanding of the Paroxysmal Nocturnal Hemoglobinuria, historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some Facts of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/paroxysmal-nocturnal-hemoglobinuria-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Paroxysmal Nocturnal Hemoglobinuria Market Report<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The market size of Paroxysmal nocturnal hemoglobinuria in the seven major markets was found to be USD 358.04 million in 2020.<\/li>\n<li>The total prevalent population of Paroxysmal nocturnal hemoglobinuria in the 7MM countries was estimated to be 8,385 cases in 2020.<\/li>\n<li>Among the European countries, Germany had the highest diagnosed population of PNH with 1,280 cases, followed by the United Kingdom which had 1,055 cases in 2020. On the other hand, Spain had the lowest number of cases as 199 cases in 2020.<\/li>\n<li>PNH is a rare condition and is thought to affect around 16 people\/million in the United Kingdom.<\/li>\n<li>As per the estimates by DelveInsight, the PNH prevalence is higher in the females and overall male and female cases are subjected to an increase in the coming years.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/paroxysmal-nocturnal-hemoglobinuria-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/paroxysmal-nocturnal-hemoglobinuria-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Paroxysmal Nocturnal Hemoglobinuria Report Highlights:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Paroxysmal Nocturnal Hemoglobinuria market report covers a descriptive overview and comprehensive insight of the PNH epidemiology and Paroxysmal Nocturnal Hemoglobinuria market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>Paroxysmal Nocturnal Hemoglobinuria market report provides insights on the current and emerging therapies.<\/li>\n<li>PNH market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/li>\n<li>Paroxysmal Nocturnal Hemoglobinuria market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the PNH market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Paroxysmal Nocturnal Hemoglobinuria treatment<\/strong> can be grouped into three approaches i.e. Supportive Treatments and immunosuppressive treatments, Treatment changing the course of the disease, and Potential Curative Treatment.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/paroxysmal-nocturnal-hemoglobinuria-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/paroxysmal-nocturnal-hemoglobinuria-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>The key players in Paroxysmal Nocturnal Hemoglobinuria market that are involved in developing therapies for PNH treatment are:-<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Apellis Pharmaceuticals<\/li>\n<li>Hoffmann-La Roche<\/li>\n<li>Novartis<\/li>\n<li>Alexion Pharmaceutical<\/li>\n<li>Regeneron Pharmaceuticals<\/li>\n<li>Achillion Pharmaceuticals<\/li>\n<li>Akari Therapeutics<\/li>\n<li>RA Pharmaceuticals<\/li>\n<li>And many others<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/paroxysmal-nocturnal-hemoglobinuria-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Paroxysmal Nocturnal Hemoglobinuria Therapies<\/a><\/strong><strong> involved are:-<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>APL-2<\/li>\n<li>Crovalimab<\/li>\n<li>LNP023<\/li>\n<li>ALXN2040<\/li>\n<li>Pozelimab<\/li>\n<li>ACH-0144471<\/li>\n<li>Coversin<\/li>\n<li>RA101495<\/li>\n<li>And many others<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Paroxysmal Nocturnal Hemoglobinuria<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Paroxysmal Nocturnal Hemoglobinuria<\/p>\n<p style=\"text-align: justify;\">4. Paroxysmal Nocturnal Hemoglobinuria: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Paroxysmal Nocturnal Hemoglobinuria: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Paroxysmal Nocturnal Hemoglobinuria Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Paroxysmal Nocturnal Hemoglobinuria Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Paroxysmal Nocturnal Hemoglobinuria: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Paroxysmal Nocturnal Hemoglobinuria<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight:<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=paroxysmal-nocturnal-hemoglobinuria-market-industry-analysis-treatment-pipeline-drugs-key-companies-including-apellis-pharmaceuticals-roche-novartis-alexion-pharmaceutical-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/paroxysmal-nocturnal-hemoglobinuria-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/paroxysmal-nocturnal-hemoglobinuria-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/paroxysmal-nocturnal-hemoglobinuria-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=paroxysmal-nocturnal-hemoglobinuria-market-industry-analysis-treatment-pipeline-drugs-key-companies-including-apellis-pharmaceuticals-roche-novartis-alexion-pharmaceutical-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paroxysmal Nocturnal Hemoglobinuria Market Paroxysmal Nocturnal Hemoglobinuria treatment has majorly been symptomatic and non-specific. Practices like an iron replacement, folic acid replenishment, blood transfusion and infection care have been in trend. Corticosteroids (e.g.prednisone) or anticoagulants (e.g. warfarin) are recommended in &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/paroxysmal-nocturnal-hemoglobinuria-market-industry-analysis-treatment-pipeline-drugs-key-companies-including-apellis-pharmaceuticals-roche-novartis-alexion-pharmaceutical-delveinsight_554781.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-554781","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/554781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=554781"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/554781\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=554781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=554781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=554781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}